Last $155.72 USD
Change Today +4.23 / 2.79%
Volume 182.7K
ICPT On Other Exchanges
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

intercept pharmaceuticals in (ICPT) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/10/14 - $497.00
52 Week Low
01/7/14 - $65.22
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

intercept pharmaceuticals in (ICPT) Related Businessweek News

No Related Businessweek News Found

intercept pharmaceuticals in (ICPT) Details

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trial to treat portal hypertension; in Phase II clinical trial for the treatment of alcoholic hepatitis; in Phase IIb clinical trial for the treatment of nonalcoholic steatohepatitis; and in Phase IIa clinical trial to treat bile acid diarrhea. The company was founded in 2002 and is headquartered in New York, New York.

122 Employees
Last Reported Date: 11/6/14
Founded in 2002

intercept pharmaceuticals in (ICPT) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $934.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $556.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $626.5K
Compensation as of Fiscal Year 2013.

intercept pharmaceuticals in (ICPT) Key Developments

Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) added to NASDAQ Biotechnology Index

Intercept Pharmaceuticals, Inc. will be added to the NASDAQ Biotechnology Index.

Intercept Pharmaceuticals, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 02:45 PM

Intercept Pharmaceuticals, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 02:45 PM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Mark Pruzanski, Founder, Chief Executive Officer, President and Director.

Intercept Pharmaceuticals, Inc. Announces the Appointment of Lisa Bright as Senior Vice President and Head of Europe, Effective November 17, 2014

Intercept Pharmaceuticals, Inc. announced the appointment of Lisa Bright as Senior Vice President and Head of Europe, effective November 17, 2014. Ms. Bright will be a member of the Intercept senior management team and will spearhead Intercept's European operations based in London as the company prepares for the first indication approval and launch of obeticholic acid (OCA). A seasoned executive who brings more than 25 years of biotech and pharmaceutical industry experience, Ms. Bright comes to Intercept from Gilead Sciences where she held positions of increasing responsibility, including Vice President, Northern Europe, and most recently Vice President, Head of Sovaldi Launch Planning for Europe, Asia, Middle East and Australasia and Vice President, Head Government Affairs for Europe, Middle East and Australasia. Ms. Bright's leadership of Sovaldi's European launch contributed to the most successful product launch in pharmaceutical history.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICPT:US $155.72 USD +4.23

ICPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ICPT.
View Industry Companies

Industry Analysis


Industry Average

Valuation ICPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,945.6x
Price/Book 12.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,794.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERCEPT PHARMACEUTICALS IN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at